Retrophin, Inc. Provides Sales Guidance for the Fourth Quarter and Fiscal Year 2015
For the fiscal year 2015, the company expects total net product sales of approximately $99.9 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.36 USD | +1.42% |
|
+7.45% | +13.90% |
07-01 | Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell 3000 Growth Index | CI |
07-01 | Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell 3000E Growth Index | CI |
1st Jan change | Capi. | |
---|---|---|
+13.90% | 778M | |
+20.22% | 126B | |
+22.77% | 118B | |
+23.26% | 27.87B | |
-18.92% | 20.95B | |
-15.13% | 16.92B | |
-14.18% | 16.18B | |
+10.00% | 14.84B | |
-46.10% | 14.79B | |
+51.45% | 14.08B |